

Francesco Costa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3878593/publications.pdf>

Version: 2024-02-01

79
papers

7,160
citations

236612

25
h-index

82410

72
g-index

87
all docs

87
docs citations

87
times ranked

6934
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
2	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	13.9	1,585
3	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet</i> , The, 2017, 389, 1025-1034.	6.3	840
4	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016, 37, ehv443.	1.0	293
5	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 2015, 350, h1618-h1618.	3.0	279
6	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	0.6	261
7	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 73, 741-754.	1.2	218
8	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017, 38, ehw525.	1.0	164
9	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 426-436.	1.1	135
10	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2592-2603.	1.2	132
11	Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. <i>European Heart Journal</i> , 2015, 36, 1242-1251.	1.0	76
12	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019, 40, 2070-2085.	1.0	64
13	Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	59
14	The Rotterdam Radial Access Research. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003129.	1.4	59
15	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. <i>American Heart Journal</i> , 2016, 174, 95-102.	1.2	53
16	Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. <i>EuroIntervention</i> , 2015, 11, 68-74.	1.4	48
17	Impact of vascular access on acute kidney injury after percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 333-338.	0.3	37
18	Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. <i>EuroIntervention</i> , 2016, 11, e1222-e1230.	1.4	35

#	ARTICLE	IF	CITATIONS
19	Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer <sc>PRODIGY</sc> trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, E19-27.	0.7	30
20	Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2020, 302, 95-102.	0.8	30
21	Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?. <i>European Heart Journal</i> , 2015, 36, 1219-1222.	1.0	29
22	Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 201, 179-181.	0.8	26
23	Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all-comer PRODIGY trial. <i>International Journal of Cardiology</i> , 2016, 212, 110-117.	0.8	26
24	Benefit of radial approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: A meta-analysis of 22,108 patients. <i>International Journal of Cardiology</i> , 2015, 179, 309-311.	0.8	25
25	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 216-226.	1.4	23
26	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018, 39, e1-e33.	1.0	22
27	Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. <i>Drugs</i> , 2017, 77, 1733-1754.	4.9	21
28	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , 2021, 17, 59-66.	1.4	21
29	Radial Artery Access for Percutaneous Cardiovascular Interventions: Contemporary Insights and Novel Approaches. <i>Journal of Clinical Medicine</i> , 2019, 8, 1727.	1.0	18
30	A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. <i>American Heart Journal</i> , 2020, 223, 44-47.	1.2	17
31	Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 211-220.	1.1	16
32	The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 630-646.	0.7	16
33	Fibrosis after Myocardial Infarction: An Overview on Cellular Processes, Molecular Pathways, Clinical Evaluation and Prognostic Value. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 16.	1.3	14
34	Role of Adenosine and Purinergic Receptors in Myocardial Infarction: Focus on Different Signal Transduction Pathways. <i>Biomedicines</i> , 2021, 9, 204.	1.4	13
35	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1298-1307.	0.8	12
36	New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress. <i>Medicina (Lithuania)</i> , 2022, 58, 530.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Anatomic Characteristics and Clinical Implications of Angiographic Coronary Thrombus. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	11
38	Characterization of the Individual Patient's Risk After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 831-834.	1.1	11
39	Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2276.	1.0	9
40	Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?. <i>Postępy W Kardiologii Interwencyjnej</i> , 2015, 3, 170-173.	0.1	8
41	Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1203-1204.	1.2	8
42	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1667-1676.	1.1	8
43	Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk. <i>Current Opinion in Cardiology</i> , 2015, 30, 325-332.	0.8	8
44	Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 581-588.	0.7	7
45	Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007705.	1.4	6
46	Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E227-E236.	0.7	6
47	Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. <i>International Journal of Cardiology</i> , 2015, 190, 242-245.	0.8	5
48	Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. <i>Journal of Clinical Medicine</i> , 2019, 8, 2016.	1.0	5
49	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006582.	0.9	5
50	Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 2380.	1.0	5
51	Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 21-34.	1.0	4
52	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. <i>Panminerva Medica</i> , 2022, 64, .	0.2	4
53	Validation of the ARC-HBR criteria in 68,874 patients undergoing PCI: A systematic review and meta-analysis. <i>Hellenic Journal of Cardiology</i> , 2022, , .	0.4	4
54	Everolimus-eluting bioresorbable vascular scaffolds implanted in coronary bifurcation lesions. <i>International Journal of Cardiology</i> , 2016, 221, 656-664.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Chronic Thrombocytopenia and Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1869-1871.	1.1	3
56	Obstructive sleep apnoea syndrome and endothelial function: potential impact of different treatment strategies—meta-analysis of prospective studies. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2331-2338.	0.8	3
57	DAPT Score to Stratify Ischemic and Bleeding Risk after Percutaneous Coronary Intervention: An Updated Systematic Review, Meta-Analysis, and Meta-Regression of 100,211 Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 687-689.	1.8	3
58	The Incidence and Impact of In-Hospital Bleeding in Patients with Acute Coronary Syndrome during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 2926.	1.0	3
59	Antithrombotic Therapy in Acute Coronary Syndrome: Striking a Happy Medium. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 782-786.	0.4	2
60	Tratamiento antitrombótico en síndrome coronario agudo: buscando el equilibrio. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 782-786.	0.6	2
61	“Ticagrelor or Prasugrel, Doctor?”—The Basis for Decision in Clinical Practice. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1283-1285.	0.8	2
62	Emboic Protection Devices in Saphenous Vein Graft Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007879.	1.4	2
63	Transesophageal contrast echocardiography is not always the gold standard method in the identification of a patent foramen ovale: A clinical case. <i>Journal of Cardiovascular Echography</i> , 2015, 25, 86.	0.1	2
64	Transfusion and Mortality After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e010225.	1.4	2
65	Impellent impeller—Switching intra-aortic balloon pump to IMPELLA-CP after ST-segment elevation myocardial infarction and refractory cardiogenic shock. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1469-1472.	0.2	1
66	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 162-163.	1.2	1
67	A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	1
68	The High Bleeding Risk Patient with Coronary Artery Disease. <i>Cardiology Clinics</i> , 2020, 38, 481-490.	0.9	1
69	Myocardial ischemia due to a recanalized chronic coronary thrombus: Angiographic and optical coherence tomography imaging insights. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1582-1583.	0.2	1
70	Coronary aneurysm formation following bare-metal stent implantation: an optical coherence tomography evaluation. <i>Minerva Cardiology and Angiology</i> , 2017, 65, 196-198.	0.4	1
71	Impact of COVID-19 pandemic on in-hospital outcomes for patients with acute coronary syndrome: a propensity-weighted, multicentre study. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	1
72	TCT-425 Rotterdam Radial Access Research: Radial Artery Access Evaluation After Coronary Procedures With Very High Resolution Ultrasound; The Puncture™s Footprint. <i>Journal of the American College of Cardiology</i> , 2015, 66, B173.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Response by Costa et al to Letter Regarding Article, "The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures": Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	0
74	Competing risks in the duration of dual antiplatelet therapy"the case for shorter treatment. , 2021, , 111-130.		0
75	Distal radial artery access for percutaneous coronary intervention: Convincing the sceptical cardiologist. International Journal of Cardiology, 2021, 339, 33-34.	0.8	0
76	Concurrent Pulmonary and Cerebral Embolism: Is Tricuspid Valve Endocarditis the Culprit?. International Journal of Cardiovascular Research, 2013, 02, .	0.1	0
77	Radial and Femoral Access in Percutaneous Intervention. , 2015, , 361-371.		0
78	Novel directions for the management of dual antiplatelet therapy in patients with coronary artery disease. Cardiovascular Medicine(Switzerland), 0, , .	0.1	0
79	686 Coronary lesion distribution in young patient presenting with acute coronary syndrome. European Heart Journal Supplements, 2021, 23, .	0.0	0